224 related articles for article (PubMed ID: 29721091)
1. Soluble CD146 is a predictive marker of pejorative evolution and of sunitinib efficacy in clear cell renal cell carcinoma.
Dufies M; Nollet M; Ambrosetti D; Traboulsi W; Viotti J; Borchiellini D; Grépin R; Parola J; Giuliano S; Helley-Russick D; Bensalah K; Ravaud A; Bernhard JC; Schiappa R; Bardin N; Dignat-George F; Rioux-Leclercq N; Oudard S; Négrier S; Ferrero JM; Chamorey E; Blot-Chabaud M; Pagès G
Theranostics; 2018; 8(9):2447-2458. PubMed ID: 29721091
[TBL] [Abstract][Full Text] [Related]
2. CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas.
Dufies M; Giuliano S; Viotti J; Borchiellini D; Cooley LS; Ambrosetti D; Guyot M; Ndiaye PD; Parola J; Claren A; Schiappa R; Gal J; Frangeul A; Jacquel A; Cassuto O; Grépin R; Auberger P; Bikfalvi A; Milano G; Escudier B; Rioux-Leclercq N; Porta C; Negrier S; Chamorey E; Ferrero JM; Pagès G
Br J Cancer; 2017 Sep; 117(7):947-953. PubMed ID: 28850564
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of VHL, HIF1A, HIF2A, VEGFA and p53 expression in patients with clear‑cell renal cell carcinoma treated with sunitinib as first‑line treatment.
Wierzbicki PM; Klacz J; Kotulak-Chrzaszcz A; Wronska A; Stanislawowski M; Rybarczyk A; Ludziejewska A; Kmiec Z; Matuszewski M
Int J Oncol; 2019 Aug; 55(2):371-390. PubMed ID: 31268155
[TBL] [Abstract][Full Text] [Related]
4. Elevated plasma interleukin 6 predicts poor response in patients treated with sunitinib for metastatic clear cell renal cell carcinoma.
Pilskog M; Nilsen GH; Beisland C; Straume O
Cancer Treat Res Commun; 2019; 19():100127. PubMed ID: 30913495
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
[TBL] [Abstract][Full Text] [Related]
6. Tumour cell expression of interleukin 6 receptor α is associated with response rates in patients treated with sunitinib for metastatic clear cell renal cell carcinoma.
Pilskog M; Bostad L; Edelmann RJ; Akslen LA; Beisland C; Straume O
J Pathol Clin Res; 2018 Apr; 4(2):114-123. PubMed ID: 29665322
[TBL] [Abstract][Full Text] [Related]
7. Low DAPK1 expression correlates with poor prognosis and sunitinib resistance in clear cell renal cell carcinoma.
Song Z; Li Z; Han W; Zhu C; Lou N; Li X; Luo G; Peng S; Li G; Zhao Y; Guo Y
Aging (Albany NY); 2020 Nov; 13(2):1842-1858. PubMed ID: 33201837
[TBL] [Abstract][Full Text] [Related]
8. Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Grünwald V; Lin X; Kalanovic D; Simantov R
Eur Urol; 2016 Dec; 70(6):1006-1015. PubMed ID: 27238653
[TBL] [Abstract][Full Text] [Related]
9. The tyrosine-kinase inhibitor sunitinib targets vascular endothelial (VE)-cadherin: a marker of response to antitumoural treatment in metastatic renal cell carcinoma.
Polena H; Creuzet J; Dufies M; Sidibé A; Khalil-Mgharbel A; Salomon A; Deroux A; Quesada JL; Roelants C; Filhol O; Cochet C; Blanc E; Ferlay-Segura C; Borchiellini D; Ferrero JM; Escudier B; Négrier S; Pages G; Vilgrain I
Br J Cancer; 2018 May; 118(9):1179-1188. PubMed ID: 29563634
[TBL] [Abstract][Full Text] [Related]
10. Tumor endothelial ELTD1 as a predictive marker for treatment of renal cancer patients with sunitinib.
Niinivirta M; Georganaki M; Enblad G; Lindskog C; Dimberg A; Ullenhag GJ
BMC Cancer; 2020 Apr; 20(1):339. PubMed ID: 32321460
[TBL] [Abstract][Full Text] [Related]
11. Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial.
Tannir NM; Jonasch E; Albiges L; Altinmakas E; Ng CS; Matin SF; Wang X; Qiao W; Dubauskas Lim Z; Tamboli P; Rao P; Sircar K; Karam JA; McDermott DF; Wood CG; Choueiri TK
Eur Urol; 2016 May; 69(5):866-74. PubMed ID: 26626617
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the breast cancer resistance protein (BCRP/ABCG2) in clear cell renal cell carcinoma.
Reustle A; Fisel P; Renner O; Büttner F; Winter S; Rausch S; Kruck S; Nies AT; Hennenlotter J; Scharpf M; Fend F; Stenzl A; Bedke J; Schwab M; Schaeffeler E
Int J Cancer; 2018 Dec; 143(12):3181-3193. PubMed ID: 30070687
[TBL] [Abstract][Full Text] [Related]
13. Validation of VEGFR1 rs9582036 as predictive biomarker in metastatic clear-cell renal cell carcinoma patients treated with sunitinib.
Beuselinck B; Jean-Baptiste J; Schöffski P; Couchy G; Meiller C; Rolland F; Allory Y; Joniau S; Verkarre V; Elaidi R; Lerut E; Roskams T; Patard JJ; Oudard S; Méjean A; Lambrechts D; Zucman-Rossi J
BJU Int; 2016 Dec; 118(6):890-901. PubMed ID: 27417418
[TBL] [Abstract][Full Text] [Related]
14. Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated With Sunitinib.
Keizman D; Sarid D; Lee JL; Sella A; Gottfried M; Hammers H; Eisenberger MA; Carducci MA; Sinibaldi V; Neiman V; Rosenbaum E; Peer A; Neumann A; Mermershtain W; Rouvinov K; Berger R; Yildiz I
Oncologist; 2016 Oct; 21(10):1212-1217. PubMed ID: 27382030
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Value of Quantitative Metabolic Metrics on Baseline Pre-Sunitinib FDG PET/CT in Advanced Renal Cell Carcinoma.
Minamimoto R; Barkhodari A; Harshman L; Srinivas S; Quon A
PLoS One; 2016; 11(4):e0153321. PubMed ID: 27123976
[TBL] [Abstract][Full Text] [Related]
16. Dyskerin and telomerase RNA component are sex-differentially associated with outcomes and Sunitinib response in patients with clear cell renal cell carcinoma.
Yuan H; Qin X; Yang Q; Liu L; Fang Z; Fan Y; Xu D
Biol Sex Differ; 2023 Jul; 14(1):46. PubMed ID: 37434223
[TBL] [Abstract][Full Text] [Related]
17. VEGF expression and response to sunitinib in patients with metastatic clear cell renal cell carcinoma.
Minardi D; Lucarini G; Santoni M; Mazzucchelli R; Burattini L; Pistelli M; Bianconi M; Di Primio R; Scartozzi M; Montironi R; Cascinu S; Muzzonigro G
Anticancer Res; 2013 Nov; 33(11):5017-22. PubMed ID: 24222145
[TBL] [Abstract][Full Text] [Related]
18. Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma.
Elfiky AA; Cho DC; McDermott DF; Rosenberg JE; Fortner B; Antràs L; Chen K; Sheng Duh M; Jayawant SS; Oh WK; Atkins MB; Choueiri TK
Urol Oncol; 2011; 29(6):756-63. PubMed ID: 20451414
[TBL] [Abstract][Full Text] [Related]
19. Ezrin is a prognostic biomarker in patients with clear cell metastatic renal cell carcinoma receiving sunitinib.
Cetin B; Gonul II; Gumusay O; Afsar B; Bilgetekin I; Ozet A; Uner A
J Cancer Res Ther; 2021; 17(2):408-413. PubMed ID: 34121685
[TBL] [Abstract][Full Text] [Related]
20. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
[No Abstract] [Full Text] [Related]
[Next] [New Search]
